Research Analysts’ Recent Ratings Changes for Sanofi (SNY)

Several brokerages have updated their recommendations and price targets on shares of Sanofi (NASDAQ: SNY) in the last few weeks:

• 5/1/2026 – Sanofi was given a new $52.00 price target by Morgan Stanley.
• 5/1/2026 – Sanofi was downgraded by Morgan Stanley from “overweight” to “equal weight”.
• 4/29/2026 – Sanofi was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 4/27/2026 – Sanofi was upgraded by Argus to “strong-buy”.
• 4/20/2026 – Sanofi was downgraded by BNP Paribas Exane from “outperform” to “neutral”. They now have a $50.00 price target on the stock.
• 4/13/2026 – Sanofi had its “neutral” rating reaffirmed by Citigroup Inc..
• 4/9/2026 – Sanofi was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 3/23/2026 – Sanofi was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 3/19/2026 – Sanofi was upgraded by Sanford C. Bernstein to “strong-buy”.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be issued a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend is Monday, May 4th. Sanofi’s dividend payout ratio is currently 49.44%.

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.